Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SKRR to Commence Uranium Drill Program to Test Conductors at Clearwater West (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Neos Therapeutics Inc. NEOS

Healthcare Drug Manufacturers - Major
Neos Therapeutics Inc is a pharmaceutical company, engaged in the development, manufacture, and commercialization of products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technologies. The product portfolio of the company includes Methylphenidate XR-ODT and Amphetamine XR oral suspension commonly prescribed medicine for the treatment of ADHD. In... see more

Recent & Breaking News (NDAQ:NEOS)

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Neos Therapeutics, Inc.

PR Newswire October 20, 2015

NEOS SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Involving Possible Securities Fraud Violations by Neos Therapeutics, Inc. and Certain Officers and Directors-- NEOS

Business Wire October 20, 2015

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neos Therapeutics, Inc. - NEOS

Accesswire October 19, 2015

Neos Therapeutics Cotempla XR-ODT FDA Update

Business Wire October 19, 2015

Neos Therapeutics to Present at the 14th Annual BIO Investor Forum on October 20, 2015

Business Wire October 14, 2015

Neos Therapeutics Announces Second Quarter 2015 Financial Results

Business Wire September 3, 2015

Neos Therapeutics Announces Date of Second Quarter 2015 Financial Results

Business Wire August 25, 2015

Neos Therapeutics Resubmits New Drug Application for FDA Review of Amphetamine Extended-Release Orally Disintegrating Tablets to Treat ADHD

Business Wire July 30, 2015

Neos Therapeutics Announces Closing of Initial Public Offering and Exercise of Underwriters' Over-Allotment Option

Business Wire July 28, 2015

Neos Therapeutics Announces Pricing of Initial Public Offering

GlobeNewswire July 23, 2015

Neos Therapeutics Announces Pricing of Initial Public Offering

GlobeNewswire July 23, 2015